58490-99-6

Usage

Uses

Used in Chemical Research:
(1E)-N-hydroxy-7-nitro-3,4-dihydronaphthalen-1(2H)-imine is used as a reagent for its role in chemical research, aiding in the study and development of new chemical compounds.
Used in Pharmaceutical Development:
(1E)-N-hydroxy-7-nitro-3,4-dihydronaphthalen-1(2H)-imine is used as an intermediate in the production of pharmaceuticals, contributing to the development of new drugs for various medical conditions.
Used in Biological and Pharmacological Research:
(1E)-N-hydroxy-7-nitro-3,4-dihydronaphthalen-1(2H)-imine is used in research for exploring its potential biological and pharmacological activities, which can lead to advancements in medicine and healthcare.

Upstream product

• 40353-34-2 7-nitro-3,4-dihydro-2H-naphthalen-1-one 

Downstream Products

• 67104-88-5 C₁₇H₁₆N₂O₅S 
• 102153-58-2 1-Chlor-7-nitro-naphthalin 
• 211372-31-5 7-Nitro-1-amino-1,2,3,4-tetrahydronaphthalene 

Relevant academic research and scientific papers

Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases

The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

Pd-catalyzed Semmler-Wolff reactions for the conversion of substituted cyclohexenone oximes to primary anilines

Homogeneous Pd catalysts have been identified for the conversion of cyclohexenone and tetralone O-pivaloyl oximes to the corresponding primary anilines and 1-aminonaphthalenes. This method is inspired by the Semmler-Wolff reaction, a classic method that exhibits limited synthetic utility owing to its forcing conditions, narrow scope, and low product yields. The oxime N-O bond undergoes oxidative addition to Pd0(PCy3)2, and the product of this step has been characterized by X-ray crystallography and shown to undergo dehydrogenation to afford the aniline product.

Synthesis of potent and selective 2-azepanone inhibitors of human tryptase

The serine protease tryptase has been associated with a broad range of allergic and inflammatory diseases and, in particular, has been implicated as a critical mediator of asthma. The inhibition of tryptase therefore has the potential to be a valuable therapy for asthma. The synthesis, employing solution phase parallel methods, and SAR of a series of novel 2-azepanone tryptase inhibitors are presented. A member of this series, 8t, was identified as a potent inhibitor of human tryptase (IC50=38 nM) with selectivity ≤330-fold versus related serine proteases (trypsin, plasmin, uPA, tPA, APC, alpha-thrombin, and FXa).

Hemoregulatory compounds

The present invention relates to novel compounds which have hemoregulatory activities and can be used to stimulate hematopoiesis and for the treatment of viral, fungal and bacterial infectious diseases.